Recent News

• 08.06.2026 - CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
• 08.03.2026 - CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
• 07.27.2026 - CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
• 06.03.2026 - CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
• 05.21.2026 - CytomX Therapeutics to Present at Upcoming June Investor Conferences
• 05.18.2026 - CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
• 05.07.2026 - CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
• 04.30.2026 - CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
• 03.18.2026 - CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
• 03.16.2026 - CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Recent Filings

• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.06.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 08.06.2026 - 8-K Current report
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - EX-99.1 EX-99.1
• 08.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.05.2026 - 3 Initial statement of beneficial ownership of securities
• 08.03.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2026 - 3 Initial statement of beneficial ownership of securities